Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia

Current Medical Research and Opinion
John Carter, Anthony Roberts

Abstract

SoloSTAR (SR) is a new pre-filled insulin pen device for administration of insulin glargine and insulin glulisine. This article reports on the usability of SR, as reported by healthcare professionals (HCPs) and participants, in clinical practice in Australia. Individuals with Type 1 or Type 2 diabetes were eligible for this 3-month observational survey. Participants were supplied with the insulin glargine SR pens, the instruction leaflet and a toll-free helpline number. Training was offered to all participants. Independent telephone interviews were conducted with participants and HCPs after 6-10 weeks of use of SR. Overall, 150 HCPs across 93 sites supported this survey. Of these, 65 HCPs (14 doctors; 51 diabetes educators, covering 1669 patients) provided feedback, with the remaining 85 HCPs not responding. All HCPs rated participant training as 'very easy' or 'easy', and most reported that SR had, in their opinion, made training easier (85%) and quicker (98%). Most of the 536 participants reported that ease of learning to use (98%), ease of using (98%) and features (> or = 89%) of SR were 'excellent' or 'good'. SR had positive impacts on various psychological aspects for people with diabetes, including helping overcome reluct...Continue Reading

References

Jan 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·D ZieglerF Lessmann
Apr 25, 2000·The Diabetes Educator·K E RobertsonR K Campbell
Mar 26, 2002·Diabetes Technology & Therapeutics·D C Klonoff
Nov 9, 2004·Clinical Therapeutics·Kent H SummersSheila M Lenox
Jan 25, 2005·Health Services Research·William L CullSuk-fong S Tang
Sep 28, 2005·Diabetes Care·William H PolonskySteven V Edelman
Sep 5, 2006·Expert Opinion on Drug Delivery·Alastair Clarke, Marie-Paule Dain
Oct 28, 2006·The American Journal of Nursing·Meredith M WhitesideElaine Pettengill
Nov 15, 2006·Annals of Medicine·Karen M GehrsGregory S Hageman
Mar 6, 2007·Expert Opinion on Drug Delivery·Alastair Clarke, Geralyn Spollett
Apr 3, 2007·American Journal of Ophthalmology·Tien Y WongA Richey Sharrett
May 4, 2007·Evaluation & the Health Professions·Emily McFarlaneCraig A Hill
Apr 11, 2008·Current Medical Research and Opinion·Toshinari AsakuraNoriaki Yohkoh
May 1, 2008·Journal of Diabetes Science and Technology·Heike HänelAndreas Pfützner
Mar 1, 2007·Journal of Diabetes Science and Technology·Alan Carter

❮ Previous
Next ❯

Citations

Sep 22, 2009·Diabetes Technology & Therapeutics·Arnd Friedrichs
Jan 1, 2010·Medical Devices : Evidence and Research·Estella M DavisPamela A Foral
Jan 22, 2015·Diabetes Technology & Therapeutics·Wojciech FendlerWojciech Mlynarski
Oct 26, 2016·Journal of Advanced Nursing·Mei-Chuan HuangYu-Yun Hsu
Jan 15, 2014·Hospital Pharmacy·Estella M DavisApril N Smith
Jul 20, 2011·American Journal of Therapeutics·Robert M Cuddihy, Sarah K Borgman
Dec 12, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Stacey A SeggelkeBoris Draznin
Feb 10, 2011·Journal of Diabetes Science and Technology·Thomas van der Burg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.